Markets

Catabasis Pharmaceuticals (CATB) Surges: Stock Moves 8.6% Higher

Catabasis Pharmaceuticals, Inc. CATB was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 24.2% in the past one-month time frame.

The company has seen two negative estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

Catabasis Pharmaceuticals currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.

Catabasis Pharmaceuticals, Inc. Price

Catabasis Pharmaceuticals, Inc. Price

Catabasis Pharmaceuticals, Inc. price | Catabasis Pharmaceuticals, Inc. Quote

A better-ranked stock in the Medical - Biomedical and Genetics industry is Emergent Biosolutions Inc. EBS, holding a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The Hottest Tech Mega-Trend of All

Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>
 


Click to get this free report

Emergent Biosolutions Inc. (EBS): Free Stock Analysis Report

Catabasis Pharmaceuticals, Inc. (CATB): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More